Do analysts recommend JYNT or SBC?

SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 78.95%. Given SBC Medical Group's stronger consensus rating and higher possible upside, analysts plainly believe SBC Medical Group is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 SBC Medical Group 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation & earnings, JYNT or SBC?

SBC Medical Group has higher revenue and earnings than Joint. SBC Medical Group is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.26 SBC Medical Group $175.17M 2.79 $50.99M $0.47 10.11

Is JYNT or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Joint's net margin of 6.49%. SBC Medical Group's return on equity of 18.47% beat Joint's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% SBC Medical Group 27.99% 18.47% 13.10%

Does the media prefer JYNT or SBC?

In the previous week, Joint and Joint both had 2 articles in the media. SBC Medical Group's average media sentiment score of 0.27 beat Joint's score of 0.00 indicating that SBC Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SBC Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer JYNT or SRTA?

Strata Critical Medical has a consensus price target of $8.00, suggesting a potential upside of 49.81%. Given Strata Critical Medical's stronger consensus rating and higher probable upside, analysts plainly believe Strata Critical Medical is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Strata Critical Medical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media favor JYNT or SRTA?

In the previous week, Joint had 1 more articles in the media than Strata Critical Medical. MarketBeat recorded 2 mentions for Joint and 1 mentions for Strata Critical Medical. Joint's average media sentiment score of 0.00 beat Strata Critical Medical's score of -0.79 indicating that Joint is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Strata Critical Medical 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate TACO or JYNT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher valuation & earnings, TACO or JYNT?

Joint has higher revenue and earnings than Berto Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Berto Acquisition N/A N/A N/A N/A N/A Joint $54.90M 2.17 $2.91M $0.27 31.26

Does the media refer more to TACO or JYNT?

In the previous week, Berto Acquisition and Berto Acquisition both had 2 articles in the media. Berto Acquisition's average media sentiment score of 1.81 beat Joint's score of 0.00 indicating that Berto Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Berto Acquisition 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer JYNT or VMD?

Viemed Healthcare has a consensus price target of $14.00, suggesting a potential upside of 57.13%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Viemed Healthcare is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Viemed Healthcare 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better valuation & earnings, JYNT or VMD?

Viemed Healthcare has higher revenue and earnings than Joint. Viemed Healthcare is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.26 Viemed Healthcare $301.61M 1.13 $14.93M $0.36 24.75

Do analysts prefer BDSX or JYNT?

Biodesix currently has a consensus price target of $31.33, indicating a potential upside of 7.31%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings & valuation, BDSX or JYNT?

Joint has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $102.94M 2.99 -$35.26M -$3.17 N/A Joint $54.90M 2.17 $2.91M $0.27 31.26

Is BDSX or JYNT more profitable?

Joint has a net margin of 6.49% compared to Biodesix's net margin of -26.97%. Joint's return on equity of 12.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Joint 6.49% 12.02% 3.47%

Does the media refer more to BDSX or JYNT?

In the previous week, Biodesix had 1 more articles in the media than Joint. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for Joint. Biodesix's average media sentiment score of 0.79 beat Joint's score of 0.00 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Joint (JYNT) Competitors

$8.44 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.38 -0.05 (-0.65%)

As of 06:14 AM Eastern

Compare

JYNT vs. SBC, SRTA, TACO, VMD, and BDSX

Should you buy Joint stock or one of its competitors? Joint's main competitors and comparable companies include SBC Medical Group (SBC), Strata Critical Medical (SRTA), Berto Acquisition (TACO), Viemed Healthcare (VMD), and Biodesix (BDSX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Joint compare to SBC Medical Group?

Joint (NASDAQ:JYNT) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Joint and Joint both had 2 articles in the media. SBC Medical Group's average media sentiment score of 0.27 beat Joint's score of 0.00 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SBC Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 78.95%. Given SBC Medical Group's stronger consensus rating and higher possible upside, analysts plainly believe SBC Medical Group is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

76.9% of Joint shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 81.7% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Joint has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

SBC Medical Group has a net margin of 27.99% compared to Joint's net margin of 6.49%. SBC Medical Group's return on equity of 18.47% beat Joint's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
SBC Medical Group	27.99%	18.47%	13.10%

SBC Medical Group has higher revenue and earnings than Joint. SBC Medical Group is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
SBC Medical Group	$175.17M	2.79	$50.99M	$0.47	10.11

Summary

SBC Medical Group beats Joint on 12 of the 15 factors compared between the two stocks.

How does Joint compare to Strata Critical Medical?

Joint (NASDAQ:JYNT) and Strata Critical Medical (NASDAQ:SRTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Strata Critical Medical has a consensus price target of $8.00, suggesting a potential upside of 49.81%. Given Strata Critical Medical's stronger consensus rating and higher probable upside, analysts plainly believe Strata Critical Medical is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

Joint has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Strata Critical Medical has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market.

Strata Critical Medical has higher revenue and earnings than Joint. Strata Critical Medical is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
Strata Critical Medical	$197.14M	2.40	$41.35M	-$0.04	N/A

Strata Critical Medical has a net margin of 15.71% compared to Joint's net margin of 6.49%. Joint's return on equity of 12.02% beat Strata Critical Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Strata Critical Medical	15.71%	-2.97%	-2.54%

76.9% of Joint shares are owned by institutional investors. Comparatively, 47.4% of Strata Critical Medical shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Comparatively, 15.5% of Strata Critical Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Joint had 1 more articles in the media than Strata Critical Medical. MarketBeat recorded 2 mentions for Joint and 1 mentions for Strata Critical Medical. Joint's average media sentiment score of 0.00 beat Strata Critical Medical's score of -0.79 indicating that Joint is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Strata Critical Medical	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Strata Critical Medical beats Joint on 9 of the 17 factors compared between the two stocks.

How does Joint compare to Berto Acquisition?

Berto Acquisition (NASDAQ:TACO) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Berto Acquisition has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Joint has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

In the previous week, Berto Acquisition and Berto Acquisition both had 2 articles in the media. Berto Acquisition's average media sentiment score of 1.81 beat Joint's score of 0.00 indicating that Berto Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Berto Acquisition	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.9% of Joint shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Joint has higher revenue and earnings than Berto Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berto Acquisition	N/A	N/A	N/A	N/A	N/A
Joint	$54.90M	2.17	$2.91M	$0.27	31.26

Joint has a net margin of 6.49% compared to Berto Acquisition's net margin of 0.00%. Joint's return on equity of 12.02% beat Berto Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Berto Acquisition	N/A	N/A	N/A
Joint	6.49%	12.02%	3.47%

Summary

Joint beats Berto Acquisition on 8 of the 9 factors compared between the two stocks.

How does Joint compare to Viemed Healthcare?

Joint (NASDAQ:JYNT) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Viemed Healthcare has a consensus price target of $14.00, suggesting a potential upside of 57.13%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Viemed Healthcare is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Joint had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 2 mentions for Joint and 0 mentions for Viemed Healthcare. Joint's average media sentiment score of 0.00 equaled Viemed Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Joint	Neutral
Viemed Healthcare	Neutral

Joint has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Viemed Healthcare has higher revenue and earnings than Joint. Viemed Healthcare is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
Viemed Healthcare	$301.61M	1.13	$14.93M	$0.36	24.75

Joint has a net margin of 6.49% compared to Viemed Healthcare's net margin of 4.81%. Joint's return on equity of 12.02% beat Viemed Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Viemed Healthcare	4.81%	10.16%	7.22%

76.9% of Joint shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Viemed Healthcare beats Joint on 8 of the 15 factors compared between the two stocks.

How does Joint compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Biodesix has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Joint has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Joint has a net margin of 6.49% compared to Biodesix's net margin of -26.97%. Joint's return on equity of 12.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Joint	6.49%	12.02%	3.47%

Joint has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$102.94M	2.99	-$35.26M	-$3.17	N/A
Joint	$54.90M	2.17	$2.91M	$0.27	31.26

Biodesix currently has a consensus price target of $31.33, indicating a potential upside of 7.31%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Biodesix had 1 more articles in the media than Joint. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for Joint. Biodesix's average media sentiment score of 0.79 beat Joint's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.0% of Biodesix shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Comparatively, 30.2% of Joint shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Joint beats Biodesix on 9 of the 17 factors compared between the two stocks.

Get Joint News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JYNT vs. The Competition

Export

Metric	Joint	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$119.34M	$9.76B	$7.22B	$12.94B
Dividend Yield	N/A	2.62%	2.57%	12.81%
P/E Ratio	31.26	34.09	275.48	25.40
Price / Sales	2.17	4.92	653.49	82.06
Price / Cash	86.77	24.58	28.13	34.74
Price / Book	8.36	5.31	10.57	6.32
Net Income	$2.91M	$313.45M	$3.49B	$358.20M
7 Day Performance	1.69%	0.58%	-0.23%	0.42%
1 Month Performance	N/A	-1.89%	-2.67%	-3.30%
1 Year Performance	-15.26%	16.30%	18.17%	5.33%

Joint Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JYNT Joint	1.8545 of 5 stars	$8.44 flat	N/A	-15.3%	$119.34M	$54.90M	31.26	330	News Coverage High Trading Volume
SBC SBC Medical Group	3.9444 of 5 stars	$4.59 +1.1%	$8.50 +85.2%	+9.2%	$472.07M	$175.17M	9.77	863	Analyst Upgrade
SRTA Strata Critical Medical	1.7228 of 5 stars	$5.29 -1.3%	$8.00 +51.2%	N/A	$467.99M	$255.98M	N/A	601
TACO Berto Acquisition	N/A	$10.47 flat	N/A	+2.1%	$341.58M	N/A	N/A	7,892
VMD Viemed Healthcare	4.0453 of 5 stars	$8.75 -1.0%	$14.00 +60.0%	+32.4%	$333.27M	$301.61M	24.31	1,382	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JYNT) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Joint (JYNT) Competitors

JYNT vs. SBC, SRTA, TACO, VMD, and BDSX

How does Joint compare to SBC Medical Group?

Summary

How does Joint compare to Strata Critical Medical?

Summary

How does Joint compare to Berto Acquisition?

Summary

How does Joint compare to Viemed Healthcare?

Summary

How does Joint compare to Biodesix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JYNT vs. The Competition

Joint Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Joint (JYNT) Competitors

JYNT vs. SBC, SRTA, TACO, VMD, and BDSX

How does Joint compare to SBC Medical Group?

Does the media prefer JYNT or SBC?

Do analysts recommend JYNT or SBC?

Do insiders & institutionals have more ownership in JYNT or SBC?

Which has more volatility & risk, JYNT or SBC?

Is JYNT or SBC more profitable?

Which has better valuation & earnings, JYNT or SBC?

Summary

How does Joint compare to Strata Critical Medical?

Do analysts prefer JYNT or SRTA?

Which has more volatility and risk, JYNT or SRTA?

Which has preferable valuation and earnings, JYNT or SRTA?

Is JYNT or SRTA more profitable?

Do institutionals & insiders have more ownership in JYNT or SRTA?

Does the media favor JYNT or SRTA?

Summary

How does Joint compare to Berto Acquisition?

Which has more volatility and risk, TACO or JYNT?

Does the media refer more to TACO or JYNT?

Do insiders and institutionals believe in TACO or JYNT?

Do analysts rate TACO or JYNT?

Which has higher valuation & earnings, TACO or JYNT?

Is TACO or JYNT more profitable?

Summary

How does Joint compare to Viemed Healthcare?

Do analysts prefer JYNT or VMD?

Does the media prefer JYNT or VMD?

Which has more risk & volatility, JYNT or VMD?

Which has better valuation & earnings, JYNT or VMD?

Is JYNT or VMD more profitable?

Do institutionals and insiders hold more shares of JYNT or VMD?

Summary

How does Joint compare to Biodesix?

Which has more volatility & risk, BDSX or JYNT?

Is BDSX or JYNT more profitable?

Which has better earnings & valuation, BDSX or JYNT?

Do analysts prefer BDSX or JYNT?

Does the media refer more to BDSX or JYNT?

Do insiders & institutionals have more ownership in BDSX or JYNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JYNT vs. The Competition

Joint Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools